Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard.
Cutaneous T-cell lymphoma is a malignancy of skin-homing T cells. This unique population of lymphocytes requires alternative therapies to those used in nodal lymphomas. Although phototherapy and nitrogen mustard have been standard treatments for decades, newer therapies have been arriving with increased frequency. Moreover, some therapies, currently used to treat other diseases, have been used with good effect. These innovative therapies are discussed, with review of current data and examples of how these therapies may be used today.
Department of Dermatology, University of Rochester School of Medicine, Rochester, NY, USA. brian_poligone@urmc.rochester.edu
Brian
B
Poligone
Peter
P
Heald
D000634:Aminoquinolines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017679:Cryotherapy; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D054018:Lasers, Excimer / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008466:Mechlorethamine / Q000627:therapeutic use*; D011701:PUVA Therapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D035703:Therapies, Investigational
D000634:Aminoquinolines; D056572:Histone Deacetylase Inhibitors; D017319:Photosensitizing Agents; D008466:Mechlorethamine; D000077271:Imiquimod